# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ernest Hemingway (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET003-SYN
- Date: 2026-04-13
- Fictional facility: St. Posthumous Health Center
- Fictional author: Walter Brandt-Ochoa, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Six-week review: phlebotomy, drinking, mood and liver MRI. **S**

## History of present illness

Mr. Hemingway returns six weeks after intake. He has had three weekly phlebotomies without dizziness, and the fourth is planned after today's blood tests. His MRI this morning has been reported. He is drinking three or four drinks a day, all in the evening, with naltrexone daily; his AUDIT-C for the past month is 7. He has had no tremor or sweats. His mood is a little better but he still wakes early and finds it hard to start writing; his PHQ-9 is 13. Sertraline 50 mg causes no side effects. Home blood pressure averages 136/84. Headaches are about twice a week. His guns remain at the club. The echocardiogram ordered at intake has not been scheduled yet. **S**

| Element | Detail |
|---|---|
| Phlebotomy | Three sessions; the fourth today |
| Alcohol | Three or four drinks a day, evenings only; AUDIT-C 7 |
| Mood | PHQ-9 13; item 9 scored 0 |
| Home blood pressure | Average 136/84 |
| MRI of the liver | Liver iron about 9.8 mg/g; stiffness 3.1 kPa; no lesion |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No dizziness after phlebotomy; tiredness a little better |
| Gastrointestinal | Negative | No abdominal pain, nausea or jaundice |
| Neurological | Positive | Headaches about twice a week; no tremor |
| Psychiatric | Positive | Early waking and low drive in the mornings; no thoughts of suicide or wishes to be dead since the last visit |

4 systems reviewed. **S**

## Current medications

- Naltrexone 50 mg oral tablet, one tablet daily, to reduce heavy drinking **S**
- Thiamine 100 mg oral tablet, one tablet daily **S**
- Sertraline 100 mg oral tablet, one tablet daily **S**
- Amlodipine 5 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 138/86 mmHg; pulse 80 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 96.2 kg; BMI 28.7 kg/m². All vital signs are synthetic.

Hemoglobin: 14.2 g/dL; MCV: 99 fL; AST: 41 U/L (high); ALT: 49 U/L; GGT: 104 U/L (high); Ferritin: 1180 ng/mL (high); PHQ-9: 13; AUDIT-C: 7. All results are synthetic.

## Change since baseline

- Hemoglobin: 15.6 g/dL at baseline, 14.2 g/dL at this visit **S**
- MCV: 102 fL (high) at baseline, 99 fL at this visit **S**
- AST: 70 U/L (high) at baseline, 41 U/L (high) at this visit **S**
- ALT: 78 U/L (high) at baseline, 49 U/L at this visit **S**
- GGT: 196 U/L (high) at baseline, 104 U/L (high) at this visit **S**
- Ferritin: 1460 ng/mL (high) at baseline, 1180 ng/mL (high) at this visit **S**
- PHQ-9: 16 at baseline, 13 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 138/86, pulse 80; weight 96.2 kg |
| Cardiovascular | Regular rhythm; no murmur |
| Abdomen | Liver edge just palpable, smooth; no spleen felt |
| Neurological | No tremor |
| Psychiatric | Engaged; mood low but brighter; no psychotic features |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Hereditary hemochromatosis on weekly phlebotomy** (E83.110). MRI shows a raised liver iron concentration with stiffness in keeping with mild fibrosis, without advanced fibrosis or cirrhosis, so a liver biopsy is not needed and liver cancer surveillance is not indicated. Ferritin is falling as expected and hemoglobin is well above the hold threshold. **S**
   - Continue weekly phlebotomy; ferritin about every ten sessions.
   - No liver cancer surveillance; fibrosis to be reassessed after iron removal.
2. **Alcohol use disorder, severe, on naltrexone** (F10.20). Down to three or four drinks a day. After seeing that his liver already has early scarring from iron and alcohol, he decided to stop drinking altogether within the month, coming down by one drink a week rather than stopping suddenly. Liver tests are close to normal on naltrexone. **S**
   - Continue naltrexone and thiamine.
   - Step down by about one drink every week or so to none; call for tremor, sweating, racing heart, confusion or seeing things.
   - Offered a mutual-help group or an alcohol counselor; he prefers to work on it in his weekly therapy.
3. **Depression on sertraline** (F32.1). PHQ-9 16 to 13 after six weeks: a partial response. Safety reviewed: no thoughts of suicide or wishes to be dead; firearms remain off-site; the 988 Suicide & Crisis Lifeline in his phone. **S**
   - Increase sertraline to 100 mg daily.
   - Continue weekly psychotherapy.
4. **Hypertension** (I10). Home average 136/84, above the target of 130/80, and still falling as he drinks less. He would rather wait one more interval before a higher dose. **S**
   - Continue amlodipine 5 mg; increase at the next visit if home readings stay above target.
   - Echocardiogram to be scheduled.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Hemoglobin before each phlebotomy (hold if under 12.0 g/dL) | Before every session; full blood count at visits | Completed today | Hemoglobin 14.2 g/dL, MCV 99 fL; all pre-session checks above 13.5 |
| Laboratory | Serum ferritin during induction phlebotomy | At diagnosis, then about every 10 to 12 phlebotomies; target 50 to 100 ng/mL | Completed today | Ferritin 1,180 ng/mL after three sessions |
| Medication safety | Weekly phlebotomy of 500 mL | Weekly during induction | Completed today | Three sessions; the fourth today |
| Imaging | Liver fibrosis staging (ferritin over 1,000 ng/mL and raised ALT) | Once at diagnosis: elastography, MRI or biopsy | Completed today | MRI today: liver iron about 9.8 mg Fe/g; stiffness 3.1 kPa, mild fibrosis; no advanced fibrosis; no lesion |
| Imaging | Liver cancer surveillance | Every six months only with cirrhosis or advanced fibrosis | Not indicated | No cirrhosis or advanced fibrosis on MRI |
| Self-management | Diet: no iron or vitamin C supplements, no raw shellfish | Every visit | Completed today | No supplements; no raw shellfish |
| Laboratory | Liver tests on naltrexone | Baseline, about one month, then every three to six months | Completed today | AST 41, ALT 49 and GGT 104 U/L at six weeks on naltrexone |
| Survey | Drinking quantity and goal (AUDIT-C, drinking diary) | Every visit | Completed today | AUDIT-C 7; three or four drinks a day; he chose to stop within the month |
| Medication safety | Opioid use and pain plan on naltrexone | Every visit | Completed today | No opioids |
| Examination | Alcohol withdrawal risk and symptoms when cutting down or stopping | Each visit while cutting down | Completed today | No withdrawal signs; one drink fewer every week or so planned |
| Self-management | Psychosocial support for alcohol use | Offer at each stage | Completed today | Mutual-help group and alcohol counseling offered; he chose to work on drinking in weekly therapy |
| Medication safety | Thiamine | Daily while drinking heavily | Completed today | Taking thiamine daily |
| Survey | Depression (PHQ-9) | At least monthly during acute treatment | Completed today | PHQ-9 13, item 9 scored 0; partial response |
| Medication safety | Sertraline adherence and side effects | Two weeks after starting or changing the dose, then each visit | Completed today | No side effects; increased to 100 mg; the behavioral health clinician checks side effects at therapy in two weeks |
| Survey | Suicide-risk review (C-SSRS screen since the last visit), safety plan, firearm storage and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | C-SSRS screen negative since the last visit; firearms remain off-site |
| Self-management | Psychotherapy (CBT) | Weekly | Completed today | Five sessions so far |
| Examination | Blood pressure, home readings, weight and cardiac auscultation | Every visit | Completed today | 138/86 in clinic; home average 136/84; weight 96.2 kg |
| Imaging | Echocardiogram | At diagnosis of stage 2 hypertension | Ordered | Ordered at intake; not yet scheduled; the clinic will follow it up |
| Examination | Post-concussion symptoms (headache frequency, sleep, concentration) | Every visit | Completed today | Headaches about twice a week |

## Goal progress

- Drinking goal chosen by him: no more than two drinks a day and none before evening, then reconsidered once the liver results are known. In progress; target 2026-06-08. **S**
- Ferritin 50 to 100 ng/mL with weekly phlebotomy, then maintenance. In progress; target 2026-08-31. **S**
- PHQ-9 below 5. In progress; target 2026-08-31. **S**
- Blood pressure below 130/80 mmHg. In progress; target 2026-08-31. **S**
- Fewer headaches and clearer thinking, so that he can write. In progress; target 2026-08-31. **S**

## Medication changes

- Stopped: Sertraline 50 mg oral tablet, one tablet daily **S**
- Started: Sertraline 100 mg oral tablet, one tablet daily **S**

## Guideline basis

- Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases (2011), American Association for the Study of Liver Diseases (Hepatology 2011;54(1):328-343)
- ACG Clinical Guideline: Hereditary Hemochromatosis (2019), American College of Gastroenterology (Am J Gastroenterol 2019;114(8):1202-1218)
- The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018), American Psychiatric Association (Am J Psychiatry 2018;175(1):86-90)
- The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020), American Society of Addiction Medicine (Journal of Addiction Medicine)
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, hypertension and depression, bipolar, and mood disorders monographs (2026), Aether Forge

## Follow-up

- Weekly phlebotomy. Fourteen-week review in eight weeks with blood count, ferritin, liver tests, PHQ-9 and AUDIT-C. Weekly psychotherapy. **S**
- Next scheduled visit 2026-06-08: fourteen-week review: phlebotomy, the decision to stop drinking, mood and blood pressure. **S**
